AirWare Labs Corp. (OTCQB: AIRW) today announced the filing of a new patent application for a revolutionary oxygen cannula delivery system, expected to launch later this year. The system will feature a proprietary cannula design, fitted with disposable nasal dilators that diffuse the stream of oxygen as it enters the nasal passage and prevent the nasal dryness, irritation and discomfort commonly reported by cannula users. The nasal dilators also work to open the nasal passage and increase airflow by up to 60%, enhancing the overall effectiveness of oxygen therapy.
“With millions of people worldwide using nasal cannulas for oxygen therapy, it’s surprising that the same issues with dryness and irritation have persisted since the 1940s,” said Jeffrey Rassás, CEO of AirWare Labs. “We’re very excited to bring to market a highly effective solution for these common complaints that will also significantly lower the risk of infection or contamination. The diffused air stream will greatly reduce dryness, and the inserts are designed to hold the cannula in place while the oxygen recipient is sleeping.”
The global market for respiratory care devices, including oxygen cannulas, is expected to reach $13.5 billion by 2015, according to market research and consulting company MarketsandMarkets.